Biogen Idec and Elan Corporation, plc have announced new data on the global utilization, safety and overall patient exposure of TYSABRI® ((natalizumab); humanized by MRCT). “These data suggest that neurologists and patients are increasingly choosing TYSABRI for the treatment of their disease.” Click here to read the full article on PharmaLive.
New Tysabri data released
News releases
Related news
First‑of‑its‑kind UK data initiative to boost early diagnosis and deliver better treatments for children with rare diseases
TYSABRI gains market approval
